Clinical trials: Degenerative; Dementia
Frontal Lobe Dementia, Frontotemporal Lobe Dementia
Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
The primary objective of the study is to determine whether memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia.
- Conditions
- Frontal Lobe Dementia, Frontotemporal Lobe Dementia, Semantic Dementia
- Trial name
- NCT00545974
- Testing
- memantine
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- University of California, San Francisco
Cognitive Dysfunction, Alzheimer Disease
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults…
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of
- Trial name
- NCT07392723
- Testing
- Alpha-Linolenic Acid (2.6 g/day)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Michal Schnaider Beeri, Ph.D.
PPA, Non-fluent Aphasia
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with…
- Conditions
- PPA, Non-fluent Aphasia, Apraxia of Speech, Primary Progressive Non-fluent Aphasia
- Trial name
- NCT01818661
- Testing
- AV-1451
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Alzheimer Disease
A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease
This is a study to evaluate biodistribution, pharmacokinetics and safety of [18F]THK-5351 positron emission computed tomography in Cognitively Healthy Subjects and Patients with Alzheimer's Disease.
- Trial name
- NCT03112096
- Testing
- [18F]THK-5351
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Asan Foundation
Corticobasal Syndrome(CBS), Primary Progressive Aphasia(PPA)
Neuroinflammation in FTLD
The goal of this observational study is to investigate the role of neuroinflammation in frontotemporal lobar degeneration (FTLD). The main aims of this study are: 1.
- Conditions
- Corticobasal Syndrome(CBS), Primary Progressive Aphasia(PPA), Progressive Supranuclear Palsy(PSP), Behavioral Variant Frontotemporal Dementia (bvFTD)
- Trial name
- NCT06870838
- Testing
- 7T MRI scan, CSF, Blood withdrawal
- Where
- 2 sites in Netherlands
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA).
- Trial name
- NCT07033481
- Testing
- Neflamapimod
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- EIP Pharma Inc
Dementia, Alzheimer Disease
Care Ecosystem: Navigating Patients and Families Through Stages of Care
This is a randomized clinical trial evaluating the benefits of a program that supports model care for persons with dementia and their family caregivers. Subjects were recruited from California, Nebraska and Iowa.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular, Lewy Body Disease
- Trial name
- NCT02213458
- Testing
- Navigated Care
- Where
- 2 sites in United States
- Volunteers
- 1,560 people
- Sponsor
- University of California, San Francisco
Alzheimer Disease, Cognitive Impairment
The Clinical Impact of the Novel Alzheimer's Blood-based Biomarkers
The goal of this observational study is to determine whether the early adoption of blood-based biomarkers for Alzheimer's disease is associated with an impact on etiological diagnosis, patient's management, emotional impact…
- Conditions
- Alzheimer Disease, Cognitive Impairment, Dementia, Neurodegenerative Diseases
- Trial name
- PLASMAR (NCT06246019)
- Testing
- Early adoption of blood-based biomarkers for Alzheimer's disease
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Hospital del Mar Research Institute (IMIM)
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD)
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
The study will explore the impact of photobiomodulation (PBM), pulsating at frequencies of red (660nm) and near-infrared (810nm)(NIR), concurrent with a ketogenic dietary protocol (serum ketones @ .5 - 2.0 mmol/L) to mediate…
- Conditions
- Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
- Trial name
- NCT03859245
- Testing
- Photobiomodulation, Ketogenic diet
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Alzheimer's Disease
24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease
This study evaluates the safety and efficacy of AADvac1 in the treatment of patients with mild Alzheimer's disease. 60% of participants will receive AADvac1 and 40% of participants will receive placebo.
- Trial name
- ADAMANT (NCT02579252)
- Testing
- AADvac1
- Where
- 42 sites in Austria, Czechia and 6 more
- Volunteers
- 208 people
- Sponsor
- Axon Neuroscience SE
Alzheimer's Disease, Mild Cognitive Impairment
A Composite MR Neuroimaging Marker for Alzheimer's Disease
The purpose of this study is to use a functional MRI (fMRI) index to compare the brain activity of healthy volunteers to that of people with mild cognitive impairment (MCI) and Alzheimer's disease.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Frontotemporal Dementia
- Trial name
- NCT01615666
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Alzheimer's Disease, Brain Diseases
CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease
Alzheimer's disease (AD) is the most common cause of dementia and currently has no disease modifying treatments or simple accurate diagnostic tests.
- Conditions
- Alzheimer's Disease, Brain Diseases, Central Nervous System Diseases, Delirium, Dementia, Amnestic, Cognitive Disorders
- Trial name
- NCT03938870
- Testing
- L-Leucine 13C6
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Dementia
Double Blind Trial of DC Polarization in FTD
This project is designed to test how direct current (DC) electrical polarization of the brain affects language and behavior in patients with frontotemporal dementia (FTD).
- Trial name
- NCT00117858
- Testing
- Anodal DC polarization of left prefrontal cortex
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Alzheimer's Disease, Fronto-temporal Dementia
Pilot Trial Evaluating Patient Experience With the MemorEM for Patients With Neurological Diseases
Primary Objective: The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device.
- Conditions
- Alzheimer's Disease, Fronto-temporal Dementia, Parkinson Disease (PD), Cortico Basal Degeneration
- Trial name
- NCT07049341
- Testing
- MemorEM
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- NeuroEM Therapeutics, Inc.
Alzheimer Disease, Frontotemporal Dementia
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
This is a first in human study that will assess the safety and diagnostic performance of [18F]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent.
- Conditions
- Alzheimer Disease, Frontotemporal Dementia, Dementia
- Trial name
- NCT05374278
- Testing
- [18F]RP-115 PET/MRI or PET/CT and MRI
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- David Wilson
Alzheimer Disease
Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia
This study seeks to measure changes in cognition through verbal and visual test procedures and changes in biomarkers of Alzheimer's disease and inflammatory and metabolic parameters that can be measure in the central nervous…
- Trial name
- NCT05227820
- Testing
- NE3107
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Neurological Associates of West Los Angeles
Neurodegenerative Diseases
Continuation Study for Latozinemab
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
- Trial name
- NCT06111014
- Testing
- Latozinemab
- Where
- 18 sites in United States, Belgium and 8 more
- Volunteers
- 17 people
- Sponsor
- Alector Inc.
Progressive Supranuclear Palsy, Corticobasal Degeneration
A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration
The goal of this trial is to evaluate the safety and tolerability of lithium in people with progressive supranuclear palsy or corticobasal degeneration.
- Trial name
- NCT00703677
- Testing
- Lithium
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 17 people
- Sponsor
- Westat
Parkinson Disease, Essential Tremor
Brain Network Activation in Patients With Movement Disorders
The diagnosis and management of movement disorders, such as Parkinson's disease (PD), parkinson-plus syndromes (PPS), dystonia, essential tremor (ET), normal pressure hydrocephalus (NPH) and others is challenging given the lack…
- Conditions
- Parkinson Disease, Essential Tremor, Dystonia, Normal Pressure Hydrocephalus
- Trial name
- BNA-MDi (NCT03269201)
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Sheba Medical Center
Opioid-Related Disorders
Tau PET Imaging in Opioid Use Disorder
The investigators plan to enroll up to 60 adult subjects in this study. There will be three groups of up to 20 subjects each in this study.
- Trial name
- NCT05651516
- Testing
- 18F-PI-2620 PET/CT
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania